Kim Tan

SpringHill is an active, value added manager which invests exclusively in life sciences companies at an early stage of their development or which are seeking development capital. The firm focuses on drug development, pharmaceutical services, medical devises, diagnostics, generics, super-generics and biogenerics sectors. The firm partners with their investee companies, aiming to add value by helping them develop their business plan or bring in key staff. Following investment, they provide mentoring to the investee businesses so they can focus on delivering milestones within budget and timeframe. In some cases, SpringHill assumes management roles and helps recruit experienced management teams and non-executive board members through their industry network. In addition, they drive corporate growth by providing external relationships to progress the investee businesses to commercialization and exit. SpringHill seeks to be the lead investor and plans for follow up investments from the start. They have experience bridging technologies, marketing, manufacturing capabilities and private equity between East and West and aim to provide such expertise to their investee companies.

Operates as a business association

Develops pharmaceutical products

Operates as social impact investment company

Operates as a network of investors and entrepreneurs for the development of SMEs

Novastar Ventures invests in companies located in East and West Africa. The firm focuses on such as education, healthcare, consumer small agri-businesses and energy sectors. It provides financing for early and growth stage capital requirements.

SpringHill Equity Partners invests in companies located in East Africa. The firm targets companies operating in the field of the consumer sector. It provides financing for growth stage capital requirements.

Develops cancer treatments pharmaceutical products